Conscious Versus General Anesthesia in TAVR

Patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR) can safely undergo the procedure under conscious sedation.

Sedación consciente vs anestesia general en el TAVI

Conscious sedation has been adopted in clinical practice as a natural way of simplifying and conducting the procedure in the least invasive way possible.

Currently, up to 50% of patients undergo TAVR under conscious sedation, but so far there was no randomized evidence on the matter.

SOLVE-TAVI was a multicenter, open-label, 2×2 factorial, randomized trial of 447 patients with aortic stenosis undergoing TAVR, comparing conscious sedation vs. general anesthesia.

The primary efficacy endpoint was a composite powered for equivalence between both strategies for anesthesia. The composite endpoint at 30 days included: all-cause mortality, stroke, infarction, infection requiring antibiotic treatment, and acute kidney injury.


Read also: FFR and iFR Discordance in up to 20% of Cases: Which One Should Inform Our Decisions?


The primary endpoint occurred in 27.2% of patients in the conscious sedation arm vs. 26.4% of patients in the general anesthesia arm (p for equivalence = 0.015).

The rates of individual components also reached significance for equivalence. All-cause mortality was 3.2% for conscious sedation vs. 2.3% for general anesthesia; as regards stroke, 2.4% vs. 2.8%; infarction, 0.5% vs. 0%; infection requiring antibiotic treatment, 21.1% vs. 22%, and acute kidney injury, 9% vs. 9.2%, respectively.

There was a lower need for inotropes or vasopressors in patients who received conscious sedation (62.8% vs. 97.3%).

Conclusion

Conscious sedation had similar results in patients with severe aortic stenosis undergoing transfemoral TAVR compared with general anesthesia. These findings suggest that conscious sedation may be used safely during the procedure.

10-1161-circulationaha-120-046451

Original Title: General versus Local Anesthesia with Conscious Sedation in Transcatheter Aortic Valve Implantation: The Randomized SOLVE-TAVI Trial.

Reference: Holger Thiele et al. Circulation. 2020 Oct 13;142(15):1437-1447. doi: 10.1161/CIRCULATIONAHA.120.046451.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

Left Bundle Branch Block after TAVR: What Is Its Impact?

Courtesy of Dr. Juan Manuel Pérez. Left bundle branch block (LBBB) is a common complication following transcatheter aortic valve replacement (TAVR), which can be either...

Multicenter Experience with 3D Intracardiac Echocardiography for Guiding Interventional Cardiac Procedures

Courtesy of Dr. Juan Manuel Pérez. Imaging techniques play a fundamental role in interventional cardiac procedures. Intracardiac echocardiography (ICE) appears as an alternative to transesophageal...

Pathology of Self-Expanding Transcatheter Aortic Bioprostheses and Hypoattenuated Leaflet Thickening

Courtesy of Dr. Juan Manuel Pérez. Despite the available long term followup data on of transcatheter aortic valve replacement (TAVR), bioprosthesis durability continues under debate....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...